Serum and Tumor Biomarkers to Predict Outcome in the eLung Trial, a Multicenter, Randomized Phase II Study of Standard Platinum Doublets (PD) Plus Cetuximab (CET) as First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).

Bruno Bastos

Serum and Tumor Biomarkers to Predict Outcome in the eLung Trial, a Multicenter, Randomized Phase II Study of Standard Platinum Doublets (PD) Plus Cetuximab (CET) as First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
State	Published - 2013

Disciplines

Medicine and Health Sciences

Cite this

@article{a0c53bc3f3e2488abdd53018ef16839c,

title = "Serum and Tumor Biomarkers to Predict Outcome in the eLung Trial, a Multicenter, Randomized Phase II Study of Standard Platinum Doublets (PD) Plus Cetuximab (CET) as First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).",

author = "Bruno Bastos",

year = "2013",

language = "American English",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Serum and Tumor Biomarkers to Predict Outcome in the eLung Trial, a Multicenter, Randomized Phase II Study of Standard Platinum Doublets (PD) Plus Cetuximab (CET) as First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).

AU - Bastos, Bruno

PY - 2013

Y1 - 2013

M3 - Article

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -